Coya Therapeutics, Inc. filed its Form 10-Q for the quarterly period ended September 30, 2026 with the U.S. Securities and Exchange Commission on November 10, 2026, reporting financial results for the three and nine months ended that date.

Key Highlights

  • Net loss of $10,617,741 for the three months ended September 30, 2026, compared to a net loss of $2,115,831 in the same quarter of 2025, according to the filing.
  • Collaboration revenue fell to $234,134 for Q3 2026, down from $3,564,254 in Q3 2025, as reported in the statements of operations.
  • Research and development expenses reached $8,570,787 for the three months ended September 30, 2026, versus $2,916,875 in the prior-year quarter.
  • Cash and cash equivalents stood at $35,802,136 as of September 30, 2026, down from $46,822,786 at December 31, 2025.
  • Accumulated deficit reached $86,426,268 as of September 30, 2026, compared to $61,963,277 at December 31, 2025.
  • January 2026 private placement raised net proceeds of $10,953,604 through the sale of 2,522,727 shares of common stock, net of issuance costs of $0.1 million.
  • Shares outstanding as of November 5, 2026 were 23,457,849, up from 20,934,456 at December 31, 2025.

Coya Therapeutics Reports Financial Results for the Nine Months Ended September 30, 2026

Coya Therapeutics, Inc. (NASDAQ:COYA), a clinical-stage biopharmaceutical company, disclosed its unaudited interim financial results in a 10-Q covering the period ended September 30, 2026. The filing shows a net loss of $24,462,991 for the nine months ended September 30, 2026, compared to a net loss of $15,517,565 for the same period in 2025. On a per-share basis, the nine-month net loss was $1.05 per share (basic and diluted), against $0.93 per share in the prior-year period, based on weighted-average shares of 23,189,440 and 16,726,108, respectively.

Total operating expenses for the nine months ended September 30, 2026 were $26,364,832, compared to $20,510,091 in the same period of 2025. Research and development expenses accounted for $17,698,034 of that total, up from $11,794,054 in the prior-year period. General and administrative expenses were $8,623,481 for the nine months ended September 30, 2026, versus $8,179,521 a year earlier. Collaboration revenue for the nine-month period was $729,026, compared to $3,985,754 in the nine months ended September 30, 2025.

Net cash used in operating activities for the nine months ended September 30, 2026 was $20,819,631, compared to $9,732,174 in the same prior-year period. The company also reported net cash used in investing activities of $909,896, related to the purchase of in-process research and development assets. Net cash provided by financing activities was $10,708,877, primarily from the January 2026 private placement proceeds. The filing also noted that the company paid $244,727 in financing costs related to an ATM Offering Program. Total stockholders' equity as of September 30, 2026 was $33,568,346, down from $43,028,230 at December 31, 2025.

What Was Disclosed

Coya Therapeutics filed its Q3 2026 Form 10-Q disclosing a net loss of $10,617,741 for the quarter and $24,462,991 for the nine-month period, alongside declining collaboration revenue, increased R&D spending, and a cash balance of $35,802,136 as of September 30, 2026.